(Q45213829)

English

A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge

scientific article published on 7 August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 December 2017

A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge (English)

1 reference

Europe PubMed Central

10 December 2017

human parainfluenza

1 reference

based on heuristic

inferred from title

author name string

Catherine E Greer

1

1 reference

Europe PubMed Central

10 December 2017

Fengmin Zhou

2

1 reference

Europe PubMed Central

10 December 2017

Harold S Legg

3

1 reference

Europe PubMed Central

10 December 2017

Zequn Tang

4

1 reference

Europe PubMed Central

10 December 2017

Silvia Perri

5

1 reference

Europe PubMed Central

10 December 2017

Barbara A Sloan

6

1 reference

Europe PubMed Central

10 December 2017

Jan Zur Megede

7

1 reference

Europe PubMed Central

10 December 2017

Yasushi Uematsu

8

1 reference

Europe PubMed Central

10 December 2017

Michael Vajdy

9

1 reference

Europe PubMed Central

10 December 2017

John M Polo

10

1 reference

Europe PubMed Central

10 December 2017

language of work or name

0 references

publication date

7 August 2006

1 reference

Europe PubMed Central

10 December 2017

1 reference

Europe PubMed Central

10 December 2017

25

1 reference

Europe PubMed Central

10 December 2017

3

1 reference

Europe PubMed Central

10 December 2017

481-489

1 reference

Europe PubMed Central

10 December 2017

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Cold adaptation of parainfluenza virus type 3: Induction of three phenotypic markers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized wit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Virus-based vectors for human vaccine applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Sindbis virus: an efficient, broad host range vector for gene expression in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

A cell line that expresses a reporter gene in response to infection by Sindbis virus: a prototype for detection of positive strand RNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

PARAINFLUENZA TYPE 3 VIRUS INFECTION IN HAMSTERS: VIROLOGIC, SEROLOGIC, AND PATHOLOGIC STUDIES.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Alphavirus replicon particles as candidate HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.07.048

1 reference

Europe PubMed Central

10 December 2017

1 reference

Europe PubMed Central

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45213829&oldid=2070155773"